Foghorn Therapeutics (FHTX)
Develops oncology drugs from a Gene Traffic Control discovery platform.
$4.07
vs last close−0.17 (−4.01%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 75.84% | 45.04M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.52% | 5.65M shares | |
| 2 holders · as of May 14, 2026 | |||
| Other | ≈ 14.64% | 8.70M shares | |
| remainder | |||
59.39M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
105 holders · 45.04M shares · 18 new positions · 57 increased · 26 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 12.67M | 21.34% | 0 | Aug 14, 2026 |
| BVF Inc/IL | 5.84M | 9.84% | 0 | Aug 14, 2026 |
| FMR LLC | 5.71M | 9.61% | −341.2K | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 4.39M | 7.40% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 2.63M | 4.42% | +262.0K | Aug 7, 2026 |
| Raymond James Financial Inc | 2.49M | 4.19% | −112.4K | Aug 14, 2026 |
| Euclidean Capital LLC | 1.57M | 2.65% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.49M | 2.52% | −478 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Noubar Afeyanincl. Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P. +7 more | 27.20% | 20.77M | 13D | Jan 13, 2026 |
| FMR LLC | 11.60% | 6.79M | 13G | May 6, 2026 |
| Deerfield Mgmt, L.P. | 8.64% | 5.14M | 13G | May 14, 2026 |
| Biotechnology Value Fund L P | 5.40% | 3.16M | 13G | May 15, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.